Gencom

Gencom Extends Capabilities To Include Genotoxicity Degradation Modeling

Gencom — Sat, 23 Feb 2008 21:34:00 GMT

Irvine CA USA February 14, 2008 Gencom announced today that the Company has extended the capabilities of its Genesys In-Silico Drug Discovery Optimization platform to include Genotoxic degradation modeling. Genotoxicity testing is commonly carried out in preclinical trials in mice, but the new in-silico methodologies developed by Gencom will advance screening capabilities, speed and accuracy and reduce the number of animals that are exposed to experimental drugs.The company already has in-silico...(read more)

Gencom Publishes Fact Sheet On Its Genesys In-Silico Drug Discovery Optimization Platform

Gencom — Sat, 23 Feb 2008 21:27:00 GMT

Genesys is a science-focused technology platform whose sole objective is to advance the discovery of human therapeutics. It was designed to optimize the entire drug discovery process; from target identification and elimination to in-silico forced degradation and dissolution modeling. The strategic objectives for Genesys were to: Enhance Discovery Performance Optimize Research Risk Management Increase Execution Success Mitigate Research Risk Costs The Genesys Drug In-Silico Discovery Optimization...(read more)

Gencom Recognized For Humanitarian Impact

Gencom — Sun, 22 Apr 2007 22:56:00 GMT

Leading Innovator in the Field of Drug Discovery Optimization Recognized By Itanium Solutions Alliance For Novel Development on the Itanium 2 Processor.

Beijing, CN – April 17, 2007 – The Itanium® Solutions Alliance (www.ItaniumSolutionsAlliance.org) announced today at the Intel Developer’s Forum that Gencom (www.GenomicComputation.com) was selected by a distinguished panel for Honorable Mention in the category of Humanitarian Impact.

The Humanitarian Impact category awards innovative use of applications running on Itanium® 2-based systems where these systems demonstrate a profound impact on humanity through research, social improvements or other humanitarian efforts.

The Itanium® Solutions Alliance is a global community of hardware, operating system and application vendors dedicated to accelerating the adoption and ongoing development of Itanium® 2-based solutions. Formed in September 2005, the Alliance is comprised of some of the most influential companies in the computing industry with a shared strategic commitment to deliver enterprise and technical computing solutions based on Intel® Itanium® 2 architecture.

The contest recognized top deployments of Itanium® 2-based systems in mission-critical computing environments in 3 categories; Humanitarian Impact, Enterprise Business Innovation, and Entrepreneurial Innovation. The Humanitarian Impact Award recognized solutions that demonstrate a profound impact on humanity through research, social improvements or other humanitarian efforts.

Stony Brook University was awarded top honors for their ground-breaking biomedical research in the areas of HIV and AIDS research. Gencom was one of ten organizations from around the globe that received honorable mentions for their submission. See http://www.itaniumsolutionsalliance.org/programs/innovationcontest/finalist_humanitarian/ for a list of finalists in the Humanitarian Impact category.

Each of the winners demonstrated innovative computing using applications that take full advantage of Intel Itanium architecture. Judges Matthew Eastwood, program vice president of IDC’s Enterprise Platform Group; William Jalby, head of Ph.D. graduate school covering economics, computer science and robotics at the University of Versailles; included Renee J. James, vice president and general manager of the Software and Solutions Group for Intel Corporation, Intel; Gale Persil, director of product management operations, Computer Associates; Chen Qiwang, Itanium product manager, PowerLeader Science & Technology Co., Ltd; and Mark K. Smith, managing director, Gelato Federation; selected the winning solutions based on the difficulty of challenge, the results produced and originality.

Michael J. Colonna, Gencom’s Founder & Chief Technology Architect, said of the award “We are honored to be recognized and humbled to be considered alongside some of the most prestigious and innovative institutions in the world. We credit Intel for providing such an amazing technology which served as the foundation of our technical architecture”. Colonna also acknowledged the Itanium Solutions Alliance for providing a forum to highlight the advantages of the Itanium® 2. He added “The Alliance is a cadre of innovative institutions that stand unified in their commitment to advance the deployment of Itanium® 2-based solutions and we are very pleased to be a contributing member.”

About Gencom, Inc.

Gencom is leading innovation in the field of discovery optimization and is advancing the current state of high performance computing for clients engaged in functional genomics and other computationally intensive drug discovery activities. The company has set the performance standard for in-silico scientific discovery and innovation. Our goal is to dramatically improve people’s lives by providing researchers with the tools to identify the cause of disease and to develop innovative therapeutics.

Gencom’s revolutionary hyper-mesh computing architecture, based upon Intel’s Itanium® 2 processor and Microsoft technologies, significantly reduces drug discovery-to-market times for its clients. The Company is based in Irvine, CA with future locations being planned for Research Triangle Park, NC and Cold Spring Harbor, NY.

For additional information about Gencom, please visit www.GenomicComputation.com.

The Gencom Logo, Discover Now and GENĕSYS are trademarks, trade names or service marks of Gencom, Inc. in the U.S.A. and/or other countries. Itanium Solutions Alliance, Itanium 2, Intel, and all other trademarks belong to their respective owners.

Gencom Takes Leading Role in Promoting "Genetic Bill of Rights"

Gencom — Sat, 27 Jan 2007 01:03:00 GMT

Leading Innovator in the Field of Drug Discovery Optimization Voices Opposition to Gene Patenting.

Irvine, CA USA - January 26, 2007 - Gencom (www.GenomicComputation.com) announced today that the Company has taken a position in the contentious debate over Gene Patenting. “The need to protect intellectual capital is paramount to success in the global economy, and we support all efforts to protect and control access to IP related to disease discovery methodologies, processes or treatments but not the disease, gene or genetic disorder that causes the disease”, said Michael J. Colonna, Gencom’s Founder & Chairman.

The debate over Gene Patenting is gaining momentum and is the subject of Dr. Michael Crichton’s latest novel “Next”. While the book, published by Harper-Collins, is fictional, Dr. Crichton has included a great deal of factual information to add fuel to the concerns over “ownership” of genes and diseases. According to Crichton, “Major hepatitis C and HIV genes are all owned. Researchers working on those diseases must worry about getting permission and paying high fees”. The U.S. Patent Office has given laboratories, private sector companies and universities the rights to 20% of the genes found in everyone’s DNA. www.NEXTgencode.com provides a glimpse of what the future may hold.

Colonna went on to say “Anything that occurs naturally in biology is off limits when it comes to patenting. We are strongly opposed to the patenting of biological data, be it genes, proteins, diseases, cellular anomalies, etc. These data belong to society and in the public domain where scientists can easily gain unrestricted access to them in order to support the development of novel therapeutics. That is not to say that any unique processes or technologies used to sequence or otherwise characterize or identify unique biological entities, or any resulting therapies, should not be patented and afforded full protection by international IP laws.”

Ever since the race between the public and private sector to map the human genome, there have been concerns over the desire of private entities to claim ownership to genes that they identified. The Bayh-Dole Act has extended the concern by allowing universities that have traditionally placed all research in the public domain, to profit by patenting discoveries from Federally-funded research, including genes and genetic disorders. According to Colonna “this will have dire implications for academia, the scientific community and society at-large.”

There is a movement to establish a “Genetic Bill of Rights” that sets out to encourage a global dialogue on the fundamental values that have been put at risk by new applications of genetics. A basic set of common principles that is essential for creating a framework for understanding the ethical, legal, social and environmental implications of biotechnology. The foundational principle of the Rights is that “All people have the right to a world in which living organisms cannot be patented, including human beings, animals, plants, microorganisms and all their parts”.

According to Colonna, “Gencom supports this movement and intends to take a leading role in facilitating a global discussion on the subject.” The Company is planning an online summit where ideas, thoughts and opinions can be expressed on the subject and encourages government, industry and community participation. Additionally, the Company hopes to stimulate individual action through contribution to the summit and communication related to gene patenting to Congress, the U.S. Patent Office and other governmental bodies in every country.

About Gencom, Inc.

Gencom’s revolutionary hyper-mesh computing architecture, based upon Microsoft technologies and Intel’s Itanium 2 processor, will significantly reduce drug discovery-to-market times for its clients by;

Enhancing Discovery Performance
Optimizing Research Risk Management
Increasing Execution Success, and
Mitigating Research Risk Costs.

The Company is based in Irvine, CA with future locations being planned for Research Triangle Park, NC and Cold Spring Harbor, NY.

For additional information about Gencom, please visit www.GenomicComputation.com or contact Lindsay Davenport at (LDavenport@GenomicComputation.com)

The Gencom Logo, Discover Now and GENĕSYS are trademarks, trade names or service marks of Gencom, Inc. in the U.S.A. and/or Gencom International, a Swiss non-operating association, in other countries. All other trademarks belong to their respective owners.